empagliflozin
Empagliflozin is a drug used to treat Diabetes Mellitus, Type 2, Healthy, Heart Failure, and other conditions. Empagliflozin is being actively studied in 37 studies and prior, has been studied in 61.
Top Sponsors | Top Sites | Top Investigators |
---|---|---|
Boehringer Ingelheim | Charite - Universitatsmedizin Berlin | Anton Borisov |
EMS | East Coast Institute for Research, LLC | CHEOL WHAN LEE, M.D., Ph.D |
Getz Pharma | The University of North Carolina at Chapel Hill | Caroline M Kistorp |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
H
Completed
- Type 2 Diabetes Mellitus
- Teneligliptin
- +2 more
- Seoul, Korea, Republic ofClinical Pharmacology, Asan Medical Center
2021-11-08
Nov 8, 2021S
Not yet recruiting
- Metabolic-associated Fatty Liver Disease
- Type 2 Diabetes
- Empagliflozin
- +2 more
- (no location specified)
2021-12-15
Dec 15, 2021O
Not yet recruiting
- type1diabetes
- Empagliflozin
- Columbus, OhioOhio State University
2021-06-07
Jun 7, 2021U
Not yet recruiting
- Postprandial Hypoglycemia
- empagliflozin
- +3 more
- Basel, SwitzerlandDepartment of Endocrinology, Diabetes and Metabolism, University
2022-01-19
Jan 19, 2022B
Active, not recruiting
- Diabetes Mellitus, Type 2
- Empagliflozin
- +2 more
- Boston, MassachusettsBringham Women Hospital
2022-04-04
Apr 4, 2022H
Recruiting
- Glycogen Storage Disease Type IB
- Empagliflozin
- Hong Kong, Hong KongHong Kong Children's Hospital
2021-08-08
Aug 8, 2021M
Not yet recruiting
- Atrial Fibrillation
- +3 more
- Empagliflozin
- Placebo
- Acquaviva Delle Fonti, Bari, ItalyMiulli General Hospital
2021-04-01
Apr 1, 2021B
Completed
- Diabetes Mellitus, Type 2
- Empagliflozin
- +3 more
- Ingelheim am Rhein, GermanyBoehringer Ingelheim
2022-01-18
Jan 18, 2022C
Active, not recruiting
- Type2 Diabetes
- Empagliflozin
- Dapagliflozin
- Cheonju, Chungcheongbuk-do, Korea, Republic ofChungbuk National University Hospital
2021-11-02
Nov 2, 2021U
Completed
- End Stage Renal Disease
- Empagliflozin
- Placebo
- Pisa, ItalyDepartment of Endocrinology and Metabolism, University of Pisa
2021-09-13
Sep 13, 2021B
Completed
- Diabetes Mellitus, Type 2
- Placebo
- Empagliflozin
- Ingelheim am Rhein, GermanyBoehringer Ingelheim
2022-01-18
Jan 18, 2022C
Not yet recruiting
- Glucose 6 Phosphatase Deficiency
- Empagliflozin
- Warsaw, PolandThe Children's Memorial Health Institute
2021-06-18
Jun 18, 2021N
Recruiting
- Crohn's Disease
- +2 more
- Empagliflozin
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022B
Completed
- Type 2 Diabetes Mellitus
- Empagliflozin
- Stockholm, SwedenBoehringer Ingelheim AB
2021-07-21
Jul 21, 2021N
Completed
- Heart Failure, Diastolic
- Diabetes Mellitus, Type 2
- Empagliflozin
- Standard care
- Moscow, Russian FederationNational Medical Research Center for Cardiology
2022-01-10
Jan 10, 2022B
Active, not recruiting
- Diabetes Mellitus, Type 2
- Empagliflozin
- Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA)
- Aarhus, DenmarkDepartment of Clinical Epidemiology - Aarhus Unversiteteshospita
2022-03-07
Mar 7, 2022G
Active, not recruiting
- Type II Diabetes Mellitus
- +2 more
- Empagliflozin
- Islamabad, PakistanUmar Diabetes Foundation
2021-12-20
Dec 20, 2021B
Active, not recruiting
- Diabetes Mellitus, Type 2
- empagliflozin
- Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
- Ingelheim am Rhein, GermanyBoehringer Ingelheim International GmbH
2022-04-05
Apr 5, 2022U
Recruiting
- Cardiovascular Diseases
- Left Ventricular Hypertrophy
- Empagliflozin
- Placebo
- Toronto, Ontario, Canada
- +3 more
2021-06-14
Jun 14, 2021B
Active, not recruiting
- Diabetes Mellitus, Type 2
- Cardiovascular Diseases
- empagliflozin
- +2 more
- Ridgefield, ConnecticutBoehringer Ingelheim Pharmaceuticals Inc
2022-03-07
Mar 7, 2022H
Completed
- Diabetes Mellitus, Type 2
- Empagliflozin
- Placebo
- Hellerup, DenmarkCenter for Diabetes Research, Gentofte Hospital
2021-06-09
Jun 9, 2021B
Not yet recruiting
- Type 2 Diabetes Mellitus
- Chronic Kidney Disease
- Finerenone (Kerendia, BAY94-8862 )
- +2 more
- Savannah, Georgia
- +12 more
2022-04-07
Apr 7, 2022B
Not yet recruiting
- Liver Diseases
- Hypertension, Portal
- BI 685509
- Empagliflozin
- (no location specified)
2022-04-04
Apr 4, 2022I
Completed
- Cardiovascular Diseases
- Empagliflozin
- Placebos
- New York, New YorkMount Sinai Heart - Icahn School of Medicine at Mount Sinai
2021-03-02
Mar 2, 2021M
Active, not recruiting
- NASH
- +7 more
- MET409 Active
- +2 more
- Fort Myers, Florida
- +1 more
2021-05-28
May 28, 2021